{"protocolSection":{"identificationModule":{"nctId":"NCT02323685","orgStudyIdInfo":{"id":"SGCI-002"},"organization":{"fullName":"Prolong Pharmaceuticals","class":"INDUSTRY"},"briefTitle":"Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)","officialTitle":"Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)"},"statusModule":{"statusVerifiedDate":"2016-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-12"},"primaryCompletionDateStruct":{"date":"2016-06","type":"ACTUAL"},"completionDateStruct":{"date":"2016-10","type":"ACTUAL"},"studyFirstSubmitDate":"2014-11-12","studyFirstSubmitQcDate":"2014-12-22","studyFirstPostDateStruct":{"date":"2014-12-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-10-26","lastUpdatePostDateStruct":{"date":"2016-10-27","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Prolong Pharmaceuticals","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Safety and effect of SANGUINATE on patients DCI following SAH.","detailedDescription":"The purpose of this study is to study the safety and effect of SANGUINATE on patients suffering from delayed cerebral ischemia after acute aneurysmal subarachnoid hemorrhage."},"conditionsModule":{"conditions":["Cerebral Ischemia"],"keywords":["DCI","Delayed Cerebral Ischemia","SAH","Subarachnoid Hemorrhage","Aneurysmal Subarachnoid Hemorrhage","Cerebral Ischemia","Brain Ischemia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":12,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"SANGUINATE™","type":"EXPERIMENTAL","description":"Single infusion of SANGUINATE (pegylated carboxyhemogloblin)","interventionNames":["Biological: SANGUINATE™"]}],"interventions":[{"type":"BIOLOGICAL","name":"SANGUINATE™","description":"Single infusion of SANGUINATE (pegylated carboxyhemogloblin)","armGroupLabels":["SANGUINATE™"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety of study drug during and following infusion as measured by vital signs, clinical signs, bioanalytical measures, or investigational drug-related adverse events","description":"Safety assessments to include vital signs, clinical signs, bioanalytical measures, or investigational drug-related adverse events","timeFrame":"Up to 30 days"},{"measure":"Impact of SANGUINATE on brain oxygenation and blood flow assessed using Postitron Emission Tomography (PET)","description":"Blood oxygenation and blood flow will be assessed using Postitron Emission Tomography (PET)","timeFrame":"Up to 30 days"}],"secondaryOutcomes":[{"measure":"Changes in neurological function measured by National Institutes of Health Stroke Scale (NIHSS)","timeFrame":"Up to 30 days"},{"measure":"Incidence, location, and size of cerebral infarction as measured by MRI","timeFrame":"Up to 30 days"},{"measure":"Changes in Blood Gases as measured by Hemoximetry","timeFrame":"Up to 30 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed and dated written informed consent by the subject or his/her legally authorized representative;\n* Modified Rankin (mRankin) score of 0 or 1 prior to the onset of subarachnoid hemorrhage;\n* Ruptured aneurysm secured by endovascular coil embolization or surgical clipping (the Procedure), not more than 72 hours after the onset of subarachnoid hemorrhage; and\n* Hunt and Hess (H\\&H) grade 3 or 4, or World Federation of Neurological Surgeons (WFNS) score 3 or 4 prior to the Procedure, and Modified Fisher (mFisher) grade 3 or 4, prior to the Procedure; or\n* Clinical signs of (\"symptomatic\") delayed cerebral ischemia; or\n* Angiographic evidence of cerebral vasospasm\n\nExclusion Criteria:\n\n* In the judgment of the Investigator the patient is not a good candidate for the study\n* Evidence of rebleed following the Procedure\n* Subarachnoid hemorrhage secondary to trauma or to arteriovenous malformation\n* Diagnosed moderate to severe pulmonary hypertension\n* Radiologically confirmed moderate to severe pulmonary edema (as shown by the presence of Kerley lines, peribronchial cuffing, thickened interlobar fissure, consolidation and/or pleural effusion)\n* History within the past 6 months and/or finding of decompensated heart failure\n* Acute myocardial infarction within 3 months prior to the administration of the study drug\n* Left ventricular ejection fraction \\<40%, as determined by prior echocardiography or clinical signs of CHF\n* Medical history or concurrent evidence of moderate to severe renal insufficiency (estimated creatinine clearance \\< 30 mL/min)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Michael N Dirringer, MD","affiliation":"Barnes Jewish Hospital/Washington University","role":"STUDY_CHAIR"},{"name":"Rajat Dhar, MD","affiliation":"Barnes Jewish Hospital/Washington University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Barnes Jewish Hospital/Washington University","city":"St. Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000013345","term":"Subarachnoid Hemorrhage"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000006470","term":"Hemorrhage"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020300","term":"Intracranial Hemorrhages"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000020521","term":"Stroke"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M9246","name":"Hemorrhage","asFound":"Hemorrhage","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemia","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Ischemia","relevance":"HIGH"},{"id":"M5484","name":"Brain Ischemia","asFound":"Cerebral Ischemia","relevance":"HIGH"},{"id":"M15825","name":"Subarachnoid Hemorrhage","asFound":"Subarachnoid Hemorrhage","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M21803","name":"Intracranial Hemorrhages","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}